Sartorius Stedim Biotech Stock Falls Below Bollinger Bands: -18.83% in One Week
The biopharmaceutical equipment specialist's stock intensifies its decline in late afternoon trading, at €153. The price is now moving below the lower boundary of its Bollinger Bands, indicating a technical oversold condition. This movement extends the punishment following the first quarter results released on April 23.
A Sharp Decline Following Quarterly Earnings Release
Sartorius Stedim Biotech has fallen 2.42% to €153 from €156.8 the previous day. Over seven days, the stock has lost 18.83%. Over three months, the decline reaches 22.53%.
The downward trend accelerated after the first quarter financial results were published on April 23. The company reported a revenue increase of 7.9% at constant exchange rates to €762 million, but a slight decrease in regular EBITDA margin to 30.7% from 30.8% a year earlier. The management mentioned pressures related to tariffs and the macroeconomic environment.
The stock had already fallen by nearly 5% on the day of the announcement. Selling pressure has continued since then. In the sector, Eurofins Scientific is down 2.84% in the session, and BioMérieux has dropped 0.93%. The CAC 40 is down by 0.32%.
Price Breaks Below the Lower Bollinger Band
The price has moved below the lower boundary of the Bollinger Bands, set at €154.95. This break below indicates an oversold configuration. The RSI is at 42, in a neutral zone, which does not yet send a signal of extreme buying or selling tension.
The stock is significantly below its moving averages. The 50-day moving average is at €172.27, about 12.6% above the current price, and the 200-day moving average is at €187.17, about 22.3% above the current price. The support threshold identified in the data is at €157.90, a level now breached during the session.
Over a year, the stock has lost 23.73%. The next financial calendar event is the publication of the semi-annual results for 2026, scheduled for July 23.
